| China | Türkei | Österreich | |
| Behandlung von Diabetes mellitus mit Stammzellen | von $18,500 | von $12,000 | von $25,000 |
Bookimed erhebt keine zusätzlichen Gebühren für dem Typ-1-Diabetes-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Typ-1-Diabetes einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Typ-1-Diabetes-Behandlungsreise nie allein.
Dr. Tian Jian Qing ist Direktor der Endokrinologie und Senior-Experte für endokrine und metabolische Therapien. Er verfügt über mehr als 20 Jahre klinische Erfahrung. Zuvor arbeitete er am General Hospital des Militärkommandos Xinjiang sowie am Renji Hospital der Shanghai Jiao Tong University.
Er hat über 20 Arbeiten in SCI-gelisteten und chinesischen Kernzeitschriften veröffentlicht. Er ist Herausgeber von vier Monografien und Mitherausgeber von vier weiteren. Er hat mehr als 1.000 Materialien zur Gesundheitsaufklärung erstellt. Seine klinischen Schwerpunkte umfassen endokrine und metabolische Erkrankungen, Dysglykämie, Dyslipidämie und Hypertonie. Außerdem behandelt er Gewichtsprobleme, Schilddrüsen- und Knochenerkrankungen, das Menopausensyndrom, PCOS sowie Gestationsdiabetes und schwangerschaftsbedingte Schilddrüsenerkrankungen.
Er bekleidet Funktionen im Ständigen Rat und in Ausschüssen der Fujian Cross-Strait Medicine & Health Exchange Association sowie der Fujian Primary Health Association. Zudem ist er in der Xiamen Medical Association und der Xiamen Medical Doctor Association tätig. Er ist stellvertretender Vorsitzender des Fachbereichs Diabetes der Xiamen Medical Association.
China is developing a chemical reprogramming technique that transforms a patient's own adult tissue cells into insulin-producing pancreatic islet cells. This breakthrough focuses on using small molecules to create pluripotent stem cells. These cells are then matured into 3D islet clusters and injected into abdominal muscle.
Bookimed Expert Insight: While these breakthroughs are monumental, patients should note that research remains concentrated in Beijing and Xiamen. Facilities like Yanda International Hospital serve millions of patients annually and maintain JCI accreditation for safety. Experts like Dr. Tian Jian Qing at Xiamen Humanity Hospital specialize in metabolic dysregulation. This expertise is vital for monitoring how lab-grown cells interact with a patient's existing endocrine system.
Patient Consensus: Patients emphasize treating this as an experimental strategy rather than a guaranteed permanent cure. Many advise asking specifically about the duration of insulin independence and potential immunosuppression needs.
International patients cannot receive stem-cell transplants for Type 1 Diabetes on demand in China. Access requires thorough medical screening, institutional approval, and strict regulatory compliance. Procedures are limited to Class 3A level III hospitals. These academic centers mandate extensive laboratory testing and eligibility reviews before acceptance.
Bookimed Expert Insight: While small commercial clinics may promise quick access, legitimate treatment happens only at massive academic centers. Yanda International Hospital serves 2,500,000 patients annually and uses Class A level III protocols. This high volume means specific slots for international patients are limited. You should prioritize hospitals with Joint Commission International accreditation to ensure the cells meet global safety standards.
Patient Consensus: Patients note that these treatments are often experimental research protocols rather than standard commercial services. Many emphasize that a legitimate offer requires deep medical screening instead of a simple payment process.
Transplanted islet grafts are eventually destroyed by the immune system without lifelong medical intervention. Modern immunosuppressive protocols delay this process, but most grafts experience progressive decline. Clinical data indicates a 40% survival rate after 20 years. Recipients often require insulin long-term.
Bookimed Expert Insight: Patient volume and multidisciplinary support are key indicators of long-term graft management quality. Yanda International Hospital in Beijing serves 2,500,000 patients annually and holds JCI accreditation. Large Class A Level III centers often have the diagnostic infrastructure to monitor rejection markers more frequently than smaller clinics.
Patient Consensus: Patients note that successful transplants usually mean reducing insulin needs rather than achieving a permanent cure. Many emphasize that preserving the graft for as long as possible is a quality-of-life victory.
Legitimate clinics differ from unproven stem-cell scams through strict regulatory oversight and evidence-based protocols. Authentic programs use therapies approved by agencies like the Joint Commission International (JCI). They focus on specific conditions rather than claiming universal cures. Avoiding scams requires verifying clinical trial registration and identifying hospital-based settings.
Bookimed Expert Insight: High-authority Chinese hospitals like Yanda International combine international protocols with massive patient volumes. Yanda serves 2,500,000 people annually and maintains Class A Level III status. This scale often indicates a legitimate infrastructure that smaller, isolated clinics lacks. Contrast this with facilities that only market to international patients and lack national accreditation.
Patient Consensus: Patients warn that any promise to fully eliminate insulin is likely predatory marketing. Legitimate trials use heavy screening and cautious language focused on preserving remaining beta-cell function.
Standard care in top-tier Chinese hospitals focuses on inpatient stabilization and advanced insulin technology. Class 3A centers utilize continuous glucose monitoring and insulin pump therapy. They integrate Western endocrinology with traditional Chinese medicine. Hospitals like Yanda International Hospital offer JCI-accredited care for complex metabolic management.
Bookimed Expert Insight: While many local centers focus on basic insulin management, JCI-accredited facilities like Yanda International Hospital serve millions of patients yearly. These high-volume centers integrate traditional Chinese medicine specifically to treat diabetic neuropathy. This combination is a standard protocol often missing in Western clinics. Dr. Tian Jian Qing at Xiamen Humanity Hospital represents the caliber of specialists found in these institutions.
Patient Consensus: Patients note that major hospitals are much better equipped for initial diagnosis and insulin titration. They emphasize learning day-to-day management skills during the inpatient stay as follow-up care can be challenging elsewhere.
The HIM protocol is an experimental cellular therapy combining islet cell neogenesis and mesenchymal stem cells to restore natural insulin production. It protects newly generated cells from autoimmune destruction. This approach aims for insulin independence without traditional immunosuppressive drugs during clinical trials in specialized centers.
Bookimed Expert Insight: Focus on JCI-accredited Class A Level III hospitals in China like Yanda International Hospital. These institutions handle over 2,500,000 patients annually and maintain the highest clinical standards required for complex endocrinology. High patient volumes often correlate with deeper experience in managing inpatient insulin titration during novel treatments.
Patient Consensus: Patients emphasize that any protocol must provide reliable basal insulin coverage to avoid rapid ketosis. Many note that hospital supervision is critical when changing regimens to ensure safety and stability.
Traditional Chinese Medicine (TCM) serves as a supportive therapy for Type 1 Diabetes. It cannot replace mandatory insulin injections. Leading Chinese hospitals use acupuncture and herbal formulas to manage complications. These methods aim to improve insulin sensitivity and reduce neuropathic pain alongside conventional protocols.
Bookimed Expert Insight: While many seek TCM in China, the most effective results come from Class A level III hospitals like Yanda International Hospital. These top-tier facilities integrate traditional methods directly with JCI-accredited international safety protocols. This structured environment ensures that herbal treatments and acupuncture are monitored by Western-trained endocrinologists. This prevents dangerous interactions between herbs and insulin that might occur in smaller, unsupervised clinics.
Patient Consensus: Patients emphasize that insulin remains non-negotiable and warn against any claims of reversing the condition with herbs. Most find TCM helpful for improving sleep and comfort but recommend checking blood sugar more frequently when starting herbal regimens.